{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:43:03Z","timestamp":1792773783588,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.kint.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T09:22:23Z","timestamp":1785316943000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Triple immunosuppressive therapy in active lupus nephritis: does one therapy really fit all?"],"prefix":"10.1016","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.07.003_bib1","doi-asserted-by":"crossref","unstructured":"Mejia-Vilet JM, Ayoub I. Front-loading response: why combination therapy should anchor initial lupus nephritis treatment. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2026.04.043.","DOI":"10.1016\/j.kint.2026.04.043"},{"key":"10.1016\/j.kint.2026.07.003_bib2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.07.003_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.kint.2026.07.003_bib4","doi-asserted-by":"crossref","unstructured":"Lichtnekert J, Anders H-J. Triple therapy is not required for all newly diagnosed cases of lupus nephritis. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2026.06.011.","DOI":"10.1016\/j.kint.2026.06.011"},{"key":"10.1016\/j.kint.2026.07.003_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.07.003_bib9","unstructured":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis (BLISS-LN). ClinicalTrials.gov Identifier: NCT01639339. Updated March 19, 2021. Accessed July 26, 2026. https:\/\/clinicaltrials.gov\/study\/NCT01639339?term=NCT01639339&rank=1"},{"key":"10.1016\/j.kint.2026.07.003_bib6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.07.003_bib10","unstructured":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN\/RPS 2003 Class III or IV Lupus Nephritis (REGENCY). ClinicalTrials.gov Identifier: NCT04221477. Updated July 21, 2026. Accessed July 26, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04221477?term=REGENCY%20lupus&rank=1"},{"key":"10.1016\/j.kint.2026.07.003_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2516150","article-title":"Efficacy and safety of obinutuzumab in active systemic lupus erythematosus","author":"Furie","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826005442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826005442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:12:12Z","timestamp":1792771932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826005442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":9,"alternative-id":["S0085253826005442"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.07.003","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple immunosuppressive therapy in active lupus nephritis: does one therapy really fit all?","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.06.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.04.043","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}